Edition:
United Kingdom

Medivir AB (MVIRb.ST)

MVIRb.ST on Stockholm Stock Exchange

38.90SEK
16 Feb 2018
Change (% chg)

0.75kr (+1.97%)
Prev Close
38.15kr
Open
38.65kr
Day's High
39.65kr
Day's Low
38.65kr
Volume
123,754
Avg. Vol
87,082
52-wk High
84.25kr
52-wk Low
35.55kr

Select another date:

Fri, Feb 2 2018

BRIEF-Medivir completes directed issue of around 155 mln SEK

* MEDIVIR HAS COMPLETED A DIRECTED SHARE ISSUE OF APPROXIMATELY 155 MSEK

BRIEF-Medivir Intends To Make A Directed Share Issue

* MEDIVIR - ‍MEDIVIR IS IN DISCUSSIONS WITH FDA ON DESIGN OF PIVOTAL PHASE III CTCL STUDY FOR REMETINOSTAT​

BRIEF-Medivir: successful completion of pre-clinical safety studies with MIV-818

* SUCCESSFUL COMPLETION OF PRE-CLINICAL SAFETY STUDIES WITH MIV-818, ENABLING START OF PHASE I CLINICAL STUDIES IN 2018 Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

BRIEF-Medivir announces new cancer project

* Medivir announces new cancer project, Leukotide, derived from its in-house nucleotide platform

BRIEF-Medivir Q3 EBITDA loss widens

* Says ‍net turnover for continuing operations totalled SEK 5.1 million (25.7 m), SEK 5.1 million (13.5 m) of which comprised Q3's royalties​

BRIEF-Medivir receives FDA fast track designation for MIV-711 for treatment of OA

* Medivir receives FDA fast track designation for MIV-711 for the treatment of OA Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

BRIEF-Medivir says positive top line data from 6-month initial phase IIa study of MIV-711

* Announces positive top line data from MIV-711-201, 6-month initial phase IIa study of MIV-711 in moderate knee osteoarthritis patients Source text for Eikon: Further company coverage:

BRIEF-Medivir: Janssen discontinues development of JNJ-4178 for hepatitis C

* Medivir announces Janssen to discontinue development of JNJ-4178 for hepatitis C

Select another date: